Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Yoh5.0
Yohimbe – Forschung
Überwiegend Mechanismus / Beobachtung
11 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Yohimbe sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1995–2025.
Basierend auf 11 Studien · 1 Meta-Analyse · 1 RCT
Konfidenz
Mittlere Konfidenz
Nach Outcome
Men's vitalityModerate Verbesserung der erektilen Funktion (am stärksten für standardisiertes Yohimbin, nicht für rohe Rinde) · 2-8 Wochen
Überwiegend Mechanismus / Beobachtung4 Studien
Cognitive function
Zu wenige bewertete Studien2 Studien
Muscle strength & power
Zu wenige bewertete Studien1 Studie
Endurance & exercise performance
Zu wenige bewertete Studien1 Studie
Heart & blood pressure
Zu wenige bewertete Studien1 Studie
Safety profile
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
7 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 1998
199520102025
1Systematische Übersicht2024
This review examines the multifaceted nature of yohimbine, delving into both its promising therapeutic potential and the associated risks.
Nowacka A, Śniegocka M, Śniegocki M, Ziółkowska E, Bożiłow D, Smuczyński W. · International journal of molecular sciences (2024)
Initially recognized for its purported aphrodisiac properties, yohimbine has been investigated for a wide range of applications, including sports or the treatment of erectile dysfunction and metabolic disorders.
However, toxicological concerns exist, particularly at higher doses.
Ongoing researches help to fully assess yohimbine's efficacy and safety profile and to explore strategies for enhancing its bioavailability and reducing toxicity.
The meta-analysis demonstrated that yohimbine is superior to placebo in the treatment of erectile dysfunction (odds ratio 3.85, 95% confidence interval 6.67 to 2.22). Serious adverse reactions were infrequent and reversible.
Ernst E et al. · The Journal of urology (1998)
Yohimbine significantly more effective than placebo for ED
Adverse events were mostly mild and reversible
Supports yohimbine (the isolated alkaloid) for ED specifically
Yohimbine, an α2 adrenergic receptor antagonist, is a well-validated pharmacological tool that has been widely employed in alcohol studies to evaluate noradrenergic activation.
Curley DE et al. · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2022)
Yohimbine reliably increases noradrenergic activity and arousal
In selected cases, a range of alternative agents can be considered (fludrocortisone, pyridostigmine, yohimbine, atomoxetine, fluoxetine, ergot alkaloids, ephedrine, phenylpropanolamine, octreotide, indomethacin, ibuprofen, caffeine, methylphenidate and desmopressin), though recommendation strength is weak and quality of evidence is low.
Eschlböck S et al. · Journal of neural transmission (Vienna, Austria : 1996) (2017)
Yohimbine raises blood pressure via sympathetic activation
Relevant to both therapeutic use and adverse-effect risk
A systematic review of ED/testosterone supplement ingredients found horny goat weed among common ingredients with only limited randomized evidence (most ingredients graded C/D).
Kuchakulla M et al. · International journal of impotence research (2021)
Common ED-supplement ingredient but limited RCT support
In this systematic review we present information relating to the effectiveness and safety of the following interventions: alprostadil (intracavernosal, intraurethral, topical), cognitive behavioural therapy, ginseng, papaverine, papaverine plus phentolamine (bimix), papaverine plus phentolamine plus alprostadil (trimix), penile prostheses, phosphodiesterase inhibitors (sildenafil, tadalafil, vardenafil), psychosexual counselling, vacuum devices, and yohimbine.
Khera M et al. · BMJ clinical evidence (2011)
Yohimbine has modest ED efficacy
PDE5 inhibitors are first-line
Yohimbine's role is secondary
7Systematische Übersicht2025
Cabergoline was the most frequently administered treatment, followed by yohimbine and bupropion. The cabergoline improved orgasm in 66% of the population and yohimbine in 55%.
Gómez-Bueno MP et al. · Actas urologicas espanolas (2025)